Ailux Biologics is the biologics division of XtalPi, a global leader in AI drug discovery. In this presentation, Barry Duplantis walks us through three case studies that showcase Ailux’s AI-powered immune repertoire mining and multi objective engineering. There are three pillars to Ailux’s technology: XtalFold, XenProT and Xentient.
XtalFold is a protein complex structure prediction algorithm. It can produce a protein complex structure starting from the primary sequence of an antibody and an antigen. XenProT was described as a bit like a version of ChatGPT for biologics. This technology can produce new biological sequences based off of prompts and constraints. Xentient is a predictive suite of AI tools. These can be used to down select, prioritise, triage biologics to meet the multi-parametric requirements that projects require.
Three Case Studies
The first case study showcased Trilux: a platform for identifying diverse, functional, developable, and humanised hits from antibody discovery programmes. The platform is so called because it uses the best of in vivo, in vitro, and in silico technologies.
Trilux integrates three discovery engines in one: XmartFluidics, an in house B cell screening platform for both plasma and memory cells; XploreSeq, a repertoire prediction algorithm to identify binders from NGS data sets; and XpeedPlay, an NGS enabled phage display platform.
Duplantis then moved to the second case study which highlighted Ailux’s ability to perform structure guided hit expansion of epitope specific and functional antibodies. This study focused on identifying antibodies that bind to specific epitopes using a structural approach, leading to the discovery of diverse and functionally relevant antibodies.
The final case study that Duplantis outlined involved optimising a dual specificity cytokine receptor through active learning modules, resulting in several novel and patentable variants.
Ailux has run 80 discovery programs with a strong track record, including multiple licensing deals and a high percentage of partners initiating additional programs. Duplantis finished the presentation by emphasising the importance of continuing to explore the immune repertoire and advancing Ailux’s AI capabilities to enhance antibody discovery and engineering processes.
